Compare AbCellera Biologics Inc (ABCL) vs Home Depot Inc (HD) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Home Depot (HD) trades at $336.64, down 4.0% over the past day, reflecting near-term market pressures. The stock shows a bullish technical signal with moving averages supporting upside, while oscillators remain neutral. Fundamentally, revenue grew to $159.51B in 2025 with a net income margin of 8.41%, though margins have compressed from prior years. Recent earnings beat expectations in Q1 2026, but Q3 2025 missed estimates. The company maintains strong profitability with ROE at 128.38% and declared a $2.33 dividend payable in June 2026.

The outlook for HD is cautiously optimistic, supported by analyst consensus and Pro segment growth, but faces headwinds from weakening big-ticket demand and rising mortgage rates. With a consensus price target of $370.59 implying ~10% upside, the stock presents a value opportunity for long-term investors, though margin pressure and housing market volatility pose risks to near-term performance.